The potential role of resveratrol as supportive antiviral in treating conditions such as COVID-19-A formulator's perspective

With an increased transmissibility but milder form of disease of the omicron variant of COVID-19 and the newer antivirals often still out of reach of many populations, a refocus of the current treatment regimens is required. Safe, affordable, and available adjuvant treatments should also be considered and known drugs and substances need to be repurposed and tested. Resveratrol, a well-known antioxidant of natural origin, shown to act as an antiviral as well as playing a role in immune stimulation, down regulation of the pro-inflammatory cytokine release and reducing lung injury by reducing oxidative stress, is such an option. New initiatives and collabo-rations will however need to be found to unleash resveratrol's full potential in the pharmaceutical market.

Automated summary

With the increased transmissibility and milder disease form of the omicron variant of COVID-19, there is a need to refocus on current treatment regimens. This includes considering safe, affordable, and available adjuvant treatments, as well as repurposing known drugs and substances. Resveratrol, a natural antioxidant, has shown potential as an antiviral and immune stimulant, reducing lung injury and pro-inflammatory cytokine release. However, new initiatives and collaborations are needed to fully unleash the potential of resveratrol in the pharmaceutical market.